229 related articles for article (PubMed ID: 11156408)
1. Stabilization and productive positioning roles of the C2 domain of PTEN tumor suppressor.
Georgescu MM; Kirsch KH; Kaloudis P; Yang H; Pavletich NP; Hanafusa H
Cancer Res; 2000 Dec; 60(24):7033-8. PubMed ID: 11156408
[TBL] [Abstract][Full Text] [Related]
2. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association.
Lee JO; Yang H; Georgescu MM; Di Cristofano A; Maehama T; Shi Y; Dixon JE; Pandolfi P; Pavletich NP
Cell; 1999 Oct; 99(3):323-34. PubMed ID: 10555148
[TBL] [Abstract][Full Text] [Related]
3. Regulation of cell migration by the C2 domain of the tumor suppressor PTEN.
Raftopoulou M; Etienne-Manneville S; Self A; Nicholls S; Hall A
Science; 2004 Feb; 303(5661):1179-81. PubMed ID: 14976311
[TBL] [Abstract][Full Text] [Related]
4. The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.
Georgescu MM; Kirsch KH; Akagi T; Shishido T; Hanafusa H
Proc Natl Acad Sci U S A; 1999 Aug; 96(18):10182-7. PubMed ID: 10468583
[TBL] [Abstract][Full Text] [Related]
5. Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity.
Koul D; Jasser SA; Lu Y; Davies MA; Shen R; Shi Y; Mills GB; Yung WK
Oncogene; 2002 Apr; 21(15):2357-64. PubMed ID: 11948419
[TBL] [Abstract][Full Text] [Related]
6. The tumour-suppressor function of PTEN requires an N-terminal lipid-binding motif.
Walker SM; Leslie NR; Perera NM; Batty IH; Downes CP
Biochem J; 2004 Apr; 379(Pt 2):301-7. PubMed ID: 14711368
[TBL] [Abstract][Full Text] [Related]
7. Membrane-binding and activation mechanism of PTEN.
Das S; Dixon JE; Cho W
Proc Natl Acad Sci U S A; 2003 Jun; 100(13):7491-6. PubMed ID: 12808147
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the cellular functions of PTEN using catalytic domain and C-terminal mutations: differential effects of C-terminal deletion on signalling pathways downstream of phosphoinositide 3-kinase.
Leslie NR; Gray A; Pass I; Orchiston EA; Downes CP
Biochem J; 2000 Mar; 346 Pt 3(Pt 3):827-33. PubMed ID: 10698713
[TBL] [Abstract][Full Text] [Related]
9. Thioredoxin-1 binds to the C2 domain of PTEN inhibiting PTEN's lipid phosphatase activity and membrane binding: a mechanism for the functional loss of PTEN's tumor suppressor activity.
Meuillet EJ; Mahadevan D; Berggren M; Coon A; Powis G
Arch Biochem Biophys; 2004 Sep; 429(2):123-33. PubMed ID: 15313215
[TBL] [Abstract][Full Text] [Related]
10. Binding of PTEN to specific PDZ domains contributes to PTEN protein stability and phosphorylation by microtubule-associated serine/threonine kinases.
Valiente M; Andrés-Pons A; Gomar B; Torres J; Gil A; Tapparel C; Antonarakis SE; Pulido R
J Biol Chem; 2005 Aug; 280(32):28936-43. PubMed ID: 15951562
[TBL] [Abstract][Full Text] [Related]
11. Interactions of phosphatase and tensin homologue (PTEN) proteins with phosphatidylinositol phosphates: insights from molecular dynamics simulations of PTEN and voltage sensitive phosphatase.
Kalli AC; Devaney I; Sansom MS
Biochemistry; 2014 Mar; 53(11):1724-32. PubMed ID: 24588644
[TBL] [Abstract][Full Text] [Related]
12. PTEN 2, a Golgi-associated testis-specific homologue of the PTEN tumor suppressor lipid phosphatase.
Wu Y; Dowbenko D; Pisabarro MT; Dillard-Telm L; Koeppen H; Lasky LA
J Biol Chem; 2001 Jun; 276(24):21745-53. PubMed ID: 11279206
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex.
Vazquez F; Grossman SR; Takahashi Y; Rokas MV; Nakamura N; Sellers WR
J Biol Chem; 2001 Dec; 276(52):48627-30. PubMed ID: 11707428
[TBL] [Abstract][Full Text] [Related]
14. Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.
Han SY; Kato H; Kato S; Suzuki T; Shibata H; Ishii S; Shiiba K; Matsuno S; Kanamaru R; Ishioka C
Cancer Res; 2000 Jun; 60(12):3147-51. PubMed ID: 10866302
[TBL] [Abstract][Full Text] [Related]
15. Phosphorylation of the PTEN tail regulates protein stability and function.
Vazquez F; Ramaswamy S; Nakamura N; Sellers WR
Mol Cell Biol; 2000 Jul; 20(14):5010-8. PubMed ID: 10866658
[TBL] [Abstract][Full Text] [Related]
16. Acute regulation of the tumour suppressor phosphatase, PTEN, by anionic lipids and reactive oxygen species.
Downes CP; Walker S; McConnachie G; Lindsay Y; Batty IH; Leslie NR
Biochem Soc Trans; 2004 Apr; 32(Pt 2):338-42. PubMed ID: 15046604
[TBL] [Abstract][Full Text] [Related]
17. Activation of synovial fibroblasts in rheumatoid arthritis: lack of Expression of the tumour suppressor PTEN at sites of invasive growth and destruction.
Pap T; Franz JK; Hummel KM; Jeisy E; Gay R; Gay S
Arthritis Res; 2000; 2(1):59-64. PubMed ID: 11219390
[TBL] [Abstract][Full Text] [Related]
18. The PTEN lipid phosphatase domain is not required to inhibit invasion of glioma cells.
Maier D; Jones G; Li X; Schönthal AH; Gratzl O; Van Meir EG; Merlo A
Cancer Res; 1999 Nov; 59(21):5479-82. PubMed ID: 10554022
[TBL] [Abstract][Full Text] [Related]
19. Allosteric activation of PTEN phosphatase by phosphatidylinositol 4,5-bisphosphate.
Campbell RB; Liu F; Ross AH
J Biol Chem; 2003 Sep; 278(36):33617-20. PubMed ID: 12857747
[TBL] [Abstract][Full Text] [Related]
20. PTEN: The down side of PI 3-kinase signalling.
Leslie NR; Downes CP
Cell Signal; 2002 Apr; 14(4):285-95. PubMed ID: 11858936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
